Simultaneous Inhibition of Thrombosis and Inflammation Is Beneficial in Treating Acute Myocardial Infarction

• Published in: International journal of molecular sciences Vol. 24; no. 8; p. 7333
• Main Authors: Vargas, Ian, Grabau, Ryan P, Chen, Junjie, Weinheimer, Carla, Kovacs, Attila, Dominguez-Viqueira, William, Mitchell, Adam, Wickline, Samuel A, Pan, Hua
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2023; MDPI
• Subjects: acute myocardial infarction; Animals; Blood clot; Evaluation; Heart attack; inflammasome; Inflammation; Inflammation - drug therapy; Medical equipment and supplies industry; Medical test kit industry; Myocardial Infarction - drug therapy; Myocardial Reperfusion Injury - drug therapy; Myocardial Reperfusion Injury - metabolism; Perflubron; perfluorocarbon nanoparticles; PPACK; Thrombin; Thrombin - therapeutic use; Thrombosis; Thrombosis - drug therapy; United States; Massachusetts; fluorine magnetic resonance spectroscopy; perfluorocarbon nanoparticles; thrombosis; PPACK; inflammation; fluorine magnetic resonance imaging; inflammasome; acute myocardial infarction
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24087333

Myocardial ischemia reperfusion injury (IRI) in acute coronary syndromes is a condition in which ischemic/hypoxic injury to cells subtended by the occluded vessel continues despite successful resolution of the thrombotic obstruction. For decades, most efforts to attenuate IRI have focused on interdicting singular molecular targets or pathways, but none have successfully transitioned to clinical use. In this work, we investigate a nanoparticle-based therapeutic strategy for profound but local thrombin inhibition that may simultaneously mitigate both thrombosis and inflammatory signaling pathways to limit myocardial IRI. Perfluorocarbon nanoparticles (PFC NP) were covalently coupled with an irreversible thrombin inhibitor, PPACK (Phe[D]-Pro-Arg-Chloromethylketone), and delivered intravenously to animals in a single dose prior to ischemia reperfusion injury. Fluorescent microscopy of tissue sections and F magnetic resonance images of whole hearts ex vivo demonstrated abundant delivery of PFC NP to the area at risk. Echocardiography at 24 h after reperfusion demonstrated preserved ventricular structure and improved function. Treatment reduced thrombin deposition, suppressed endothelial activation, inhibited inflammasome signaling pathways, and limited microvascular injury and vascular pruning in infarct border zones. Accordingly, thrombin inhibition with an extraordinarily potent but locally acting agent suggested a critical role for thrombin and a promising therapeutic strategy in cardiac IRI.